S‐adenosyl L‐methionine inhibits azoxymethane‐induced colonic aberrant crypt foci in F344 rats and suppresses human colon cancer Caco‐2 cell growth in 3D culture
Open Access
- 26 October 2007
- journal article
- carcinogenesis
- Published by Wiley in International Journal of Cancer
- Vol. 122 (1) , 25-30
- https://doi.org/10.1002/ijc.23031
Abstract
S-Adenosyl L-methionine (SAM) is a universal methyl group donor to various intermediary metabolites, hormones, proteins, neurotransmitters, phospholipids and nucleic acids. Deficiency of folate, which plays a role in the synthesis of SAM leads to increased risk for colon cancer. This study tested the effectiveness of SAM supplementation in protecting against azoxymethane (AOM)-induced colon carcinogenesis in male F344 rats. We also tested the effect of SAM on cyclooxygenase-2 (COX-2) in a macrophage cell line. Further, we developed a 3-D culture model using Caco-2 cells to test the effect of SAM on tumor spheroid size and number. Groups of rats were given the experimental diet containing either 0-, 400- or 800-ppm SAM, 1 week before the first AOM injection and continued until 8 weeks. In the control group, AOM produced a substantial number of aberrant crypt foci (ACF) (96 ± 8). Dietary administration of SAM significantly reduced the number of total ACF (400 ppm SAM, 68 ± 7.3, p < 0.01 and 800 ppm SAM, 57 ± 7.1, p < 0.001). SAM significantly decreased AOM-induced colonic multicrypt foci in a dose-dependent manner. Suppression of Lipopolysaccharide (LPS) induced COX-2 protein expression was observed in a RAW264.7 cell line. We established growth of Caco-2 cells as spheroids, in a 3D matrix of collagen and matrigel. Treatment with SAM decreased both size and number of spheroids in a dose-dependent manner (p < 0.0001). These observations demonstrate for the first time that SAM can reduce the occurrence of ACF in AOM treated male F344 rats and suppress formation of human tumor spheroids and expression of COX-2.Keywords
This publication has 39 references indexed in Scilit:
- Celecoxib for the Prevention of Sporadic Colorectal AdenomasNew England Journal of Medicine, 2006
- β-Escin inhibits colonic aberrant crypt foci formation in rats and regulates the cell cycle growth by inducing p21waf1/cip1 in colon cancer cellsMolecular Cancer Therapeutics, 2006
- Cardiovascular Risk Associated with Celecoxib in a Clinical Trial for Colorectal Adenoma PreventionNew England Journal of Medicine, 2005
- Low doses of β-carotene and lutein inhibit AOM-induced rat colonic ACF formation but high doses augment ACF incidenceInternational Journal of Cancer, 2004
- Cardiovascular thrombotic events in arthritis trials of the cyclooxygenase-2 inhibitor celecoxib**The investigators had full access to the data and complete control over the design, conduct analysis, interpretation, and description of the study. The sponsor of the study had no role in study design, data collection, data analysis, data interpretation, or in writing the report. The views expressed are those of the investigators alone.The American Journal of Cardiology, 2003
- Taking Cell-Matrix Adhesions to the Third DimensionScience, 2001
- The Effect of Celecoxib, a Cyclooxygenase-2 Inhibitor, in Familial Adenomatous PolyposisNew England Journal of Medicine, 2000
- Risk factors for colon neoplasia—epidemiology and biologyEuropean Journal Of Cancer, 1995
- S-Adenosyl-L-MethionineDrugs, 1989
- Observation and quantification of aberrant crypts in the murine colon treated with a colon carcinogen: Preliminary findingsCancer Letters, 1987